Clearside Biomedical Inc. (CLSD)
0.90
-0.02 (-1.95%)
At close: Apr 01, 2025, 3:59 PM
0.91
1.45%
After-hours: Apr 01, 2025, 07:55 PM EDT
Company Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration.
The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences.
Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Clearside Biomedical Inc.
| Country | United States |
| IPO Date | Jun 2, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. |
Contact Details
Address: 900 North Point Parkway Alpharetta, Georgia United States | |
| Website | https://www.clearsidebio.com |
Stock Details
| Ticker Symbol | CLSD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001539029 |
| CUSIP Number | 185063104 |
| ISIN Number | US1850631045 |
| Employer ID | 45-2437375 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | President, Chief Executive Officer & Director |
| Charles A. Deignan | Chief Financial Officer |
| Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D. | Chief Medical Officer |
| Jenny R. Kobin | Head of Investor Relations |
| Leslie B. Zacks J.D. | Secretary |
| Rafael V. Andino | Senior Vice President of Engineering & Manufacturing |
| Rick McElheny | Senior Vice President of Corporate Development & Alliance Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 04, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 24, 2025 | 4 | Filing |
| Feb 21, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Feb 13, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 4 | Filing |
| Jan 10, 2025 | 4 | Filing |
| Jan 10, 2025 | 4 | Filing |
| Dec 12, 2024 | 8-K | Current Report |